UPPSALA, SWEDEN / ACCESS Newswire / June 30, 2025 / The extraordinary general meeting in Senzime AB (STO:SEZI)(OTCQX:SNZZF), corp. reg. no 556565-5734 (the "Company") was held on 30 June 2025, whereby the shareholders primarily resolved on the following matter. All resolutions were unanimous.

Resolution on the approval of the board of directors' resolution on a directed share issue

In accordance with previously published information, the board of directors resolved 2 June 2025 on a directed issue of shares, subject to the subsequent approval of the extraordinary general meeting. The general meeting resolved today to approve the board of directors' resolution on a directed issue of a maximum of 700,000 shares. The right to subscribe for new shares shall, with deviation from the shareholders' pre-emption rights, belong to Adam Dahlberg.

The Company's share capital will increase by a maximum of SEK 87,500 through a directed issue of a maximum of 700,000 shares. The subscription price for the shares in the new issue is SEK 4.60 per share. Subscription shall be made by cash payment or on a subscription list not later than 4 July 2025.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: [email protected]

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: [email protected]

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

SOURCE: Senzime



View the original
on ACCESS Newswire


Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]